A combination of two immunotherapy drugs, ipilimumab and nivolumab, stops or reverses the progression of advanced melanoma – with long term survival rates hitting an all-time high – according to a study presented at the ESMO Congress.

A cutting-edge form of non-invasive imaging technology can track the response of malignant melanoma cells to treatment, researchers have found.

Testing for a panel of metabolites in the blood can pick out which patients are likely to respond to a drug for skin cancer, new research reports.